Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01680341 · ClinicalTrials.gov registry record · Phase 3
Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 272
- Enrollment target
NCT01680341 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 272 participants.
The verdict
NCT01680341, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 272 participants
- Enrollment target
Study Summary
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of the trial is to compare the efficacy and safety of two different titration algorithms for insulin degludec/insulin aspart (IDeg/IAsp) in subjects with type 2 diabetes mellitus previously treated with insulin glargine.
Interventions
- DRUG insulin degludec/insulin aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2012-08-31 |
| Est. Completion | 2013-08-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01680341
The ClinicalTrials.gov registry entry for NCT01680341 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which insulin degludec/insulin aspart is the first listed.
NCT01680341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01680341 about?
NCT01680341 is a clinical study titled "Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine". This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of the trial is to compare the efficacy and safety of two different titration algorithms for insulin degludec/insulin aspart (IDeg/IAsp) in subjects with type 2 diabetes mellitus previously treated with ...
What is the current status of trial NCT01680341?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 272 participants. The study started on 2012-08-31. Estimated completion is 2013-08-22.
What interventions are being tested in trial NCT01680341?
The interventions under investigation include: insulin degludec/insulin aspart (DRUG).
Who is sponsoring clinical trial NCT01680341?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.